诱导化疗的II期试验,用于高级鼻状细胞癌的诱导化疗
Kevin J Contrera1, Renata Ferrarotto2, Brandon Gunn3
1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
概括
诱导化疗 (IC) 随后的响应导向治疗对先进的鼻腔状细胞癌 (SCC) 是有前途的. 这种方法改善了这种具有挑战性的癌症患者的疾病控制和器官保存率.
科学领域:
- 在瘤学瘤学.
- 头部和部手术 头部和部手术
- 医学瘤学 医学瘤学
背景情况:
- 经过初级手术治疗的晚期鼻腔状细胞癌 (SCC) 的结果在历史上很差.
- 需要新的治疗策略来改善这些患者的疾病控制和器官保存.
研究的目的:
- 评估诱导化疗 (IC) 在改善疾病控制和器官保存方面对晚期鼻腔SCC患者的疗效.
- 评估IC和响应导向治疗后的整体应答率,局部控制,无进展生存率 (PFS) 和整体生存率 (OS).
主要方法:
- 一项II期临床试验招募了31名II-IV期,M0鼻腔SCC患者.
- 根据反应,患者接受了IC (docetaxel,cisplatin,fluorouracil),随后进行化学放射治疗 (CRT) 或辅助放射治疗/CRT的手术.
- 主要终点包括整体反应率和局部区域控制;次要终点包括PFS,OS,器官保存和毒性.
主要成果:
- 在28名可评估患者中观察到总体响应率为82.1%.
- 两年的局部区域对照和PFS率分别为64.3%和52.4%. 平均生存期为47.4个月.
- 在63%的患者中,在2年内存活的器官得到了保存,避免了重大手术切除.
结论:
- 诱导化疗与响应导向局部治疗相结合,为先进的鼻腔SCC提供了有希望的疾病控制.
- 这一策略增强了器官的保存,潜在地改善了晚期鼻腔SCC患者的生活质量.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.4K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
148
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
148
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174